Ken Griffin Sanofi Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$48.54 - $58.53 $16.7 Million - $20.2 Million	345,000 Added 91.37%	722,600 $41.7 Million
Q2 2024 Aug 14, 2024	SELL	$45.39 - $50.36 $14.5 Million - $16.1 Million	-319,200 Reduced 45.81%	377,600 $18.3 Million
Q1 2024 May 15, 2024	SELL	$45.75 - $52.48 $1.07 Million - $1.23 Million	-23,400 Reduced 3.25%	696,800 $33.9 Million
Q4 2023 Feb 14, 2024	BUY	$43.13 - $54.79 $573,629 - $728,707	13,300 Added 1.88%	720,200 $35.8 Million
Q3 2023 Nov 14, 2023	BUY	$50.95 - $55.2 $19.2 Million - $20.8 Million	376,100 Added 113.69%	706,900 $37.9 Million
Q2 2023 Aug 14, 2023	BUY	$50.45 - $57.18 $2.72 Million - $3.09 Million	54,000 Added 19.51%	330,800 $17.8 Million
Q1 2023 May 15, 2023	SELL	$45.86 - $54.45 $7.53 Million - $8.95 Million	-164,300 Reduced 37.25%	276,800 $15.1 Million
Q4 2022 Feb 14, 2023	SELL	$38.86 - $48.55 $66,062 - $82,535	-1,700 Reduced 0.38%	441,100 $21.4 Million
Q3 2022 Nov 14, 2022	BUY	$37.22 - $100.5 $4.73 Million - $12.8 Million	127,200 Added 40.3%	442,800 $16.8 Million

822

268M

1.9M

Ticker SNY
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,508,100,096
Market Cap $121B
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antib...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.